The Clinical Utility of FLT3 Mutation Testing in Acute Leukemia: A Canadian Consensus.
FMS-like tyrosine kinase 3 (FLT3) mutations are detected in approximately 20–30% of patients with acute myeloid leukemia (AML), with the presence of a FLT3 internal tandem duplication (FLT3-ITD) mutation being associated with an inferior outcome. Assessment of FLT3 mutational status is now essential...
| Published in: | Current Oncology Vol. 30; no. 12; pp. 10410 - 10437 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Published: |
MDPI
Dec2023
|
| Online Access: | View this record in EBSCOhost |